Use of INOpulse — inhaled nitric oxide — lessened pulmonary arterial pressure, and the resistance to blood flow in arteries that supply blood to the lungs, in people with pulmonary hypertension (PH) associated with pulmonary fibrosis (PH-PF), top-line results from a Phase 2 trial show. These results add to…
In the U.S., 61% of people with idiopathic pulmonary fibrosis (IPF) are prescribed approved anti-fibrotic therapies, namely Ofev (nintedanib) and Esbriet (pirfenidone), analysis of data from the U.S. Pulmonary Fibrosis (PF) Foundation Patient Registry shows. In turn, almost 40% of IPF patients are not prescribed either…
People with idiopathic pulmonary fibrosis have shorter telomeres — the protective caps at the end of chromosomes — but shortening may occur prior to disease onset. The study with that finding, “From organ to cell: Multi-level telomere length assessment in patients with idiopathic pulmonary fibrosis,” was published…
The antibiotic azithromycin (AZT), frequently prescribed for fighting bacterial infections, has anti-fibrotic effects and promotes the death of fibroblasts — cells promoting fibrosis, or scarring — in people with idiopathic pulmonary fibrosis (IPF), a new study shows. These findings suggest the potential of AZT as a therapeutic…
Throughout 2019, Pulmonary Fibrosis News provided you daily coverage of breakthrough discoveries, promising therapies, and clinical trials related to pulmonary fibrosis (PF). As we look forward to bringing more news to patients, family members, and caregivers dealing with PF in 2020, here are the top 10 most-read articles of 2019,…
A model of the human lung constructed with the help of tissue samples from 10 idiopathic pulmonary fibrosis (IPF) patients details changes in gene activity that precede evident fibrosis, a study reports. This model is a sort of genetic roadmap to IPF progression that may help researchers find treatments for…
Exposure to dust in the workplace for 10 years or longer seems to have no detrimental effect on the response of patients with idiopathic pulmonary fibrosis (IPF) to anti-fibrotic treatment with Esbriet (pirfenidone) or Ofev (nintedanib), a study has found. The study “Antifibrotic treatment response and…
People with non-small cell lung cancer (NSCLC) who also have pulmonary fibrosis and emphysema are at a greater risk of acute flares following cancer treatment that includes chemotherapy, surgery, or radiotherapy, a study from South Korea reports. The study “Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in…
April Kloxin, PhD, has received the 2019 National Institutes of Health (NIH) Director’s New Innovator Award to develop next-generation materials and tools to help accelerate research on idiopathic pulmonary fibrosis (IPF). Kloxin, a professor at the University of Delaware, is one of 60 researchers across the U.S. to win…
Citryll and Lonza have teamed up to develop Citryll’s candidate antibody, called CIT-013, as a therapy for inflammatory diseases, including idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis, the companies announced. CIT-013 is designed to inhibit the formation of web-like structures known as neutrophil extracellular traps (NETs),…
Get regular updates to your inbox.
